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Use of animal models of inherited and induced von Willebrand factor (VWF) deﬁciency continues to advance the knowledge
of VWF-related diseases: von Willebrand disease (VWD), thrombotic thrombocytopenic purpura (TTP), and coronary artery
thrombosis. First, in humans, pigs, and dogs, VWF is essential for normal hemostasis; without VWF bleeding events are severe and
can be fatal. Second, the ADAMTS13 cleavage site is preserved in all three species suggesting all use this mechanism for normal
VWF multimer processing and that all are susceptible to TTP when ADAMTS13 function is reduced. Third, while the role of VWF
in atherogenesis is debated, arterial thrombosis complicating atherosclerosis appears to be VWF-dependent. The diﬀerences in the
VWF gene and protein between humans, pigs, and dogs are relatively few but important to consider in the design of VWF-focused
experiments. These homologies and diﬀerences are reviewed in detail and their implications for research projects are discussed.
The current status of porcine and canine VWD are also reviewed as well as their potential role in future studies of VWF-related
disorders of hemostasis and thrombosis.
1.Introduction
Animal models of von Willebrand factor (VWF) deﬁciency,
both inherited and induced, have provided key insights into
VWF-related diseases. This paper focuses on the current
status of knowledge of porcine and canine VWF and von
Willebrand disease (VWD) and how investigations with
these animals have advanced the understanding of the seem-
inglyparadoxicalrolesofVWFinhemostasisandthrombosis
as well as atherogenesis [1].
In humans, pigs, and dogs, VWF is a large, adhesive
glycoprotein that supports hemostasis by mediating platelet
adhesion to injured vessel surfaces. Porcine and canine
VWD mirror type 3 human VWD, phenotypically exhibiting
a severe mucosal and cutaneous bleeding diathesis that most
often involves nasal, oral, gastrointestinal, and genitouri-
nary mucosa. Without prompt treatment, bleeding can be
crippling or fatal in all three species. In addition, humans
and animals with VWD are often recognized when excessive
bleeding occurs in association with relatively minor trauma
or surgery. Aﬀected pigs and dogs have undetectable VWF
antigen, activity, and multimers (Figure 1, Table 1). The
inheritance pattern across species occurs in an autosomal
fashion[2–6].Understandingthemolecularandbiochemical
similarities and diﬀerences between human, porcine, and
canine VWF and VWD has proven seminal in characteriz-
ing critical protein-protein interactions involved in VWF-
mediated hemostasis and thrombosis.2 Thrombosis
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Figure 1: Multimer distribution of von Willebrand factor antigen
in normal (NL) and von Willebrand disease (VWD) human, dog,
and pig plasma samples. Human plasmas were obtained from
George King Bio-Medical, Inc., Overland Park, Kansas. The human
VWD plasma was from a patient with severe type 3VWD plasma
with VWF:RCo 15IU/dl and VWF:Ag 1IU/dl. The dog and
pig plasmas were prepared at the Francis Owen Blood Research
Laboratory at the University of North Carolina at Chapel Hill using
normal and severe VWD animals that had no detectible activity or
antigen in either species. None of the subjects had recently been
transfused with VWF-containing products. Anti-VWF antibodies
for immunostaining were purchased from Dako (A082, Carpintera,
CA) (1.5% agarose gel) [7–9]. The identity of the very bottom band
seen in all lanes is unknown but is a consistent ﬁnding in multiple
laboratories and is also seen in murine VWD plasma [7–11]. It is
possible that this band simply represents nonspeciﬁc binding of
the antibody to the leading edge of the proteins at the end of the
electrophoresis procedure.
2.PorcineVWF and VWD
The porcine VWF gene is on pig chromosome 5q21, a
regionthatissyntenicwithhumanchromosome12p13.2,the
location of the human gene [12, 13]. The human VWF gene
is located near the telomere, perhaps in part accounting for
the high frequency of mutations resulting in various types of
VWD, while the pig VWF gene is more centromeric. Porcine
VWD appears to be among the oldest recognized animal
modelsofaninheritedbleedingdisorder[14].Themolecular
defect in porcine VWD has been linked to the VWF locus,
but the precise molecular mechanism has remained elusive
[15].
The complete cDNA sequence of porcine VWF pre-
dicts a protein of 2,807 amino acids, six residues shorter
than human VWF (Figure 2)[ 17–19]. Porcine and human
VWF share 84.3% identity, with additional 7% conser-
vative substitutions. The propeptide and mature portions
of porcine VWF are equally homologous to the human
sequence. Both human and porcine pre-pro-VWF contain
234 cysteines conserved in perfect register. Vicinal cysteine
motifs (CXXC) thought to be involved in disulﬁde isomerase
activity [20] are also conserved in D1, D2, and D3 domains
of each of these species. Using the human numbering
system for reference, the following residues are deleted from
porcine VWF: G215 (mid-D1 domain), GGLV1241–1244
(D3/A1 domain boundary), and 1494S (A2 domain). The
deleted residues 1241–1244 are located within a negatively
charged region ﬂanking the amino terminal side of the A1
domain disulﬁde loop that is involved in interaction with
the platelet-binding agonist, ristocetin. This region is also
critical to the regulation of VWF binding to platelet GP1b
under physiologic conditions and maintenance of the A1
loop in an unreactive conﬁguration. Porcine plasma VWF
spontaneously binds human platelets in the absence of an
agonist such as ristocetin or botrocetin, and the deletion
of these four residues in this regulatory area of human
VWF-GP1b binding may help explain this observation
[2, 4, 17, 21–23]. Interestingly, botrocetin supports pig
VWF and pig platelet agglutination but ristocetin does
not [4, 21–23]. Botrocetin also supports agglutination of
pig platelets by human VWF [22]. In humans, a D1472H
polymorphism is associated with decreased ristocetin activ-
ity, and pigs have a leucine at the homologous position
(Figure 2)[ 24]. The pig platelet Gp1b sequence is con-
served (not shown) suggesting the D1472L substitution in
pig VWF may, in part, account for the relative lack of
ristocetin reactivity. The RGD sequence is conserved and
likely mediates platelet integrin αIIbβ3 binding (Figure 2).
Recombinant porcine VWF traﬃcked to storage granules,
is eﬃciently multimerized and secreted, and spontaneously
agglutinates human platelets [18].
3.CanineVWF andVWD
The canine VWF gene has been localized to canine chro-
mosome 27 (http://www.ncbi.nlm.nih.gov/gene/399544)i n
a region that is syntenic with human chromosome 12p13.2.
Like human VWD, canine VWD appears to be the most
prevalent inherited bleeding disorder in various strains of
dogs, and, thus, there is signiﬁcant interest in detection and
characterization of the disease and ﬁnding new treatments in
all species [3, 31–34]. The Chapel Hill, canine VWD strain
was derived from a show-dog strain of Scottish Terriers and
thiscolonywasestablishedin1978fromasingleheterozygote
[4]. This causative mutation in the Chapel Hill strain of
canine type 3 VWD is due to a single nucleotide deletion
in the canine VWD sequence at base pair 255 that causes a
frameshift and a premature stop codon in exon 4 [35]. These
V W Dd o g sm a k en od e t e c t a b l eV W Fm R N Ao rp r o t e i n .
The complete cDNA sequence of canine VWF predicts
a protein of 2,813 amino acids and thus is identical in
the number of amino acids to human VWF (Figure 2)[ 36,
37]. The full-length human and canine VWF are 87.1%
identical at the nucleotide level and 86.2% at the protein
level, with an additional 6% conservative substitutions. The
propeptide and mature portions of canine VWF are 87.3 and
92.8% homologous, respectively, to the human sequence.
Like porcine VWF, canine pre-pro-VWF contains 234 cys-
teines conserved in perfect register with the homologous
portion of human VWF. Vicinal cysteine motifs (CXXC)
are also conserved in D1, D2, and D3 domains of each of
these species. Canine VWF does not react with ristocetin;
botrocetin however, is a reliable canine VWF activator and
supports the agglutination of canine platelets by canine and
human VWF [4, 21, 22]. The reason for the lack of ristocetinThrombosis 3
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Figure 2: Alignments of Human, Porcine, and Canine VWF. (a) Region of D /D3 domain highlighting the F.VIII:C binding region
(underlined). (b) Region of A1 domain showing the conserved 1272–1458 disulﬁde bonds (C1272 and C1458) in red and GP1b binding
sites in black underlined. The D1472H human polymorphism site is highlighted in green. (c) Region of A2 domain showing the ADAMTS13
cleavagesite(underlined).(d)RegionofA3domainhighlightingCollagenbindingsite.(e)RegioninC1domainindicatingtheRGDbinding
siteofintegrinαIIb/βIII.TheVWFaminoacidsequenceswereanalyzedbyClustalWmultiplesequencealignmentprogram[16]andderived
from NCBI Accession NP 000543 (Human), AF052036 and AY004876 (Porcine), and NP 001002932 (Canine).4 Thrombosis
Table 1: Diﬀerential correction of phenotype of VWD swine by transplantation of liver, kidney, bone marrow, and lung.
VWF
Transplant
procedure
Cell(s) synthesizing
VWF Plasma Platelet F.VIII Bleeding time [25] Thrombosis References
None None None None Low Prolonged Not done [14, 25]
Normal liver to
VWD
Hepatic
endothelium
Near normal to
normal Not done Near normal
to normal
Near normal to
normal Not done [26]
Normal kidney to
VWD
Presumed
endothelium None Not done Low Prolonged Not done [26]
Normal bone
marrow to VWD Megakaryocyte Little to none Present Low Prolonged No [9, 27, 28]
VWD bone marrow
to normal Endothelium Normal Absent Normal Near normal to
normal Yes [9, 28]
Normal Lung to
VWD
Pulmonary
endothelium
∼5% Absent Prolonged Not done [29]
Adapted with permission from Brinkhous KM, Reddick RL, Read MS, Nichols TC, Bellinger DA, Griggs TR. von Willebrand factor, and animal models:
contributions to gene therapy, thrombotic thrombocytopenic purpura, and coronary artery thrombosis. Mayo Clin Proc. 1991; 66:733–742 [30].
reactivity may in part be explained by the D1472P amino
acid substitution in canine VWF similar to that in porcine
VWF as described above (Figure 2)[ 24]. The dog platelet
Gp1b sequence has an M239T substitution that does not
appear to have a “gain of function” substitution as reported
for the M239V mutation in human platelet GP1b [24]. It is
also possible that botrocetin more speciﬁcally activates VWF
than does ristocetin [38]. The RGD sequence is conserved
and most likely mediates platelet integrin αIIbβ3 binding
in humans, pigs, and dogs. Recombinant canine VWF
established VWF-dependent Weibel-Palade body formation
in cultured primary VWD endothelial cells [35].
4.Research UtilizingVWDPigsandDogs
4.1. Replacement Products. Pigs and dogs with VWD have
been used to determine safety, eﬃcacy, pharmacodynamics,
and pharmacokinetics in the preclinical testing of plasma-
derived and recombinant human VWF (rhVWF) [10, 39–
42]. Importantly, rhVWF reduces the saline bleeding time
[25]fr om>15minutesto ∼5min ut es[10].Thecorrectionof
the saline bleeding time may portend support of hemostasis
when rhVWF is given to VWF-deﬁcient humans.
Infusion of plasma-derived and recombinant human
VWF into VWD pigs and rhVWF into VWD dogs is
accompanied by a delayed rise in factor VIII activity (F.VIII).
Conversely, when human F.VIII is infused into VWD dogs,
the half-life of the infused F.VIII is markedly reduced when
compared to infusing the same amount of human F.VIII
into hemophilia A dogs with normal VWF levels [43]. Taken
together, these data are consistent with human VWF binding
to and stabilization of F.VIII in both species in vivo.
InVWDdogs,thehalf-lifeofrhVWFisbetween10.2and
13.0 hours [10] and the half-life of plasma-derived canine
VWF is between 12 and 18 hours [44]. In VWD pigs, the
half-life of rhVWF is ∼10 to 16 hours [11, 39], and the half
life of plasma derived porcine VWF is between 10 and 18
hours [11, 45]. Thus, both pigs and dogs with VWD appear
to clear human and species-speciﬁc VWF in a comparable
fashion.TheresultsofpreclinicaltestingofrhVWFhavebeen
predictive of the half-life found in early testing in human
subjects [46].
4.2. VWF Secretion with DDAVP and VWF mRNA Upreg-
ulation by rhIL-11. Recombinant human IL-11 (rhIL-11,
Neumega), a glycoprotein 130- (gp130-) signaling cytokine
that is approved for treatment of thrombocytopenia, has
been shown to induce elevations in VWF and F.VIII in
humans and mice [47]. In these initial studies, it was unclear
if the mechanism for VWF elevation was mediated by
increased secretion or increased production by upregulation
of VWF mRNA. If the latter mechanisms were shown to
be correct, then rhIL-11 could be used as an additional or
alternative therapy to 1-desamino-8-D-arginine vasopressin
(DDAVP), a standard therapy for increasing VWF levels in
humans through the Weibel-Palade body secretory pathway
[34, 48, 49]. To compare DDAVP and rhIL-11, dog models
were informative since canine but not murine species
respond to DDAVP. rhIL-11 produces a gradual, sustained
elevation of VWF and F.VIII levels in both normal and het-
erozygous VWD (VWF +/−) dogs, while DDAVP produces
a rapid, nonsustained increase. rhIL-11 treatment produces
a 2.5 to 11-fold increase in VWF mRNA in normal dogs but
not in homozygous (VWF −/−) VWD dogs, thus identifying
amechanismforelevationofplasmaVWFinvivo.M o r eo v e r ,
dogs pretreated with rhIL-11 retain a DDAVP-releasable
pool of VWF and F.VIII, suggesting that rhIL-11 does not
signiﬁcantly alter traﬃcking of these proteins to or from
storage pools. The half-life of infused VWF is unchanged
by rhIL-11. These results strongly suggest that rhIL-11 and
DDAVP raise plasma VWF levels by diﬀerent mechanisms,
and that rhIL-11, like DDAVP, could be an alternative to
plasma-derived products for some VWD or hemophilia
A patients who are unresponsive to DDAVP or in whom
DDAVP is contraindicated [50]. Likewise, rhIL-11 therapy
could also reduce use of plasma products in some patients.Thrombosis 5
It is important to bear in mind that DDAVP causes an
immediate release of VWF, and tachyphylaxis limits repeated
dosing in the short term. In contrast, rhIL-11 induces a
sustained increase of VWF that, once established over a few
days, appears to persist until administration is discontinued.
Thus, the two drugs may well be complementary in many
patients if shown to be safe in clinical trials.
Recently, rhIL-11 was administered subcutaneously to
nine subjects with mild or type 1 VWD [51]( 5 F ,4 M ,a g e
21–49yr) in an FDA-approved phase 2 open label, dose
escalation study [7]. The drug was well tolerated and these
data conﬁrm that rhIL-11 increases VWF in humans with
mild or type 1 VWD by means other than the DDAVP
releasable pool of VWF, and possibly by increasing VWF
mRNA. To our knowledge, if this mechanism was conﬁrmed
in additional studies, rhIL-11 would be the ﬁrst medication
for treating an inherited bleeding disorder that actually
targets the relevant gene in situ. These encouraging results
have provided the foundation for obtaining FDA permission
to perform two phase 2 eﬃcacy studies in mild or type 1
VWD patients, the ﬁrst in patients with menorrhagia and
the second in patients undergoing elective surgery. These
ongoing studies will determine if the results with rhIL-11
therapy found in the VWD dogs and the phase 2 dose
escalation study can be translated into a safe, new treatment
for VWF-deﬁcient humans.
4.3. Atherosclerosis. The role of VWF in atherosclerosis has
been a subject of debate. A mechanism linking VWF to
atherosclerosis is based on the fact that VWF mediates
platelet adhesion to injured arterial walls, thus delivering
platelet contents, including platelet-derived growth factor
(PDGF), to the arterial wall. The hypothesis is that relatively
high concentrations of PDGF promote atherogenesis at focal
points of vascular injury [52–54]. The corollary is that the
absence of VWF reduces atherogenesis.
Since dogs tend not to get atherosclerosis, pigs are a
more appropriate animal model in which to test these
hypotheses[55].Todate,variationsinthedegreeofcoronary
and abdominal aortic atherosclerosis have been reported
for normal and VWD pigs [56–64]. However, these results
seem to be impacted by cholesterol levels. In a retrospective
study, polymorphisms in the apolipoprotein B100 genotype
were found to signiﬁcantly inﬂuence the severity of high-
fat diet-induced atherosclerotic plaque formation in VWD
and normal swine without regards to the VWD genotype
[65]. Humans with various types of VWD including type
3 are not protected from developing coronary and aortic
atherosclerosis but may develop fewer occlusive thrombi
with ensuing organ infarction [66, 67]. Thus, VWF may
mediate thrombotic complications of atherosclerosis rather
than atherogenesis per se as discussed next.
4.4. VWD and Occlusive Arterial Thrombosis. The potential
role of VWF in the development of arterial thrombosis noted
in VWD humans with atherosclerosis has been studied in
pigs and dogs. VWD pigs with or without atherosclerosis
and VWD dogs do not develop occlusive arterial thrombosis
in the Folts stenosis and injury model [8, 64, 68]. In addi-
tion, neutralizing VWF activity interrupts VWF-dependent
arterial thrombosis in nonatherosclerotic pigs with normal
VWF expression [69, 70]. Several molecules that inhibit
VWF activity have been developed as potential therapeutic
agents, and this work has recently been reviewed [71]. One
of the most promising novel approaches is the aptamer
ARC1779 [72–74]. Aptamers are synthetic nucleotides that
bind with high aﬃnity to a target protein and neutralize its
function. The current status of the VWF-binding aptamer
ARC1779 suggests that it will be a safe and eﬀective new
therapeutic that addresses unmet needs for treating patients
with arterial thrombotic diseases, particularly those that are
VWF mediated [75].
VWF serves as a carrier for plasma F.VIII in humans,
pigs, and dogs and thereby protects F.VIII from degradation
by activated protein C [76]. This carrier function may
also deliver F.VIII to sites of arterial injury and localize
F.VIII activity to sites of VWF and platelet attachment on
exposed subendothelium and promote thrombosis [77]. In
addition, hemophilia A dogs (i.e., no detectable F.VIII but
normal VWF) form occlusive arterial thrombosis as readily
as normal dogs using the same experimental model [8]. In
pigs, neutralizing VWF activity while leaving F.VIII activity
intact prevents the development of occlusive thrombosis
[69]. Human subjects with hemophilia A that lack F.VIII
have serious impairment of thrombin generation but are
not protected from myocardial infarction or thrombosis
complicating aortic atherosclerosis [78–80]. Moreover, VWF
level in humans also correlates directly with thrombosis risk
andinverselywithbleedingrisk[1].Theseresultssupportthe
hypothesis that VWF has an intrinsic property that supports
arterialthrombosisindependentofitsassociationwithF.VIII
in humans, pigs, and dogs.
4.5. VWD and Bleeding Time Prolongation. In humans, pigs,
and dogs, VWF is synthesized in endothelial cells that
store and secrete the protein into the subendothelium and
plasma (Table 1)[ 81, 82]. VWF is also synthesized in human
and porcine megakaryocytes and is present in human and
porcine platelet alpha granules [27, 83–85]. VWF does not
appear to be synthesized in canine megakaryocytes nor is
it present in platelet alpha granules [8, 35]. Studies in the
three species have shown that bleeding time prolongation is
variablyaﬀectedbydecreasedplateletVWFandplasmaVWF
[9, 27, 86, 87]. In porcine VWD and human type 3 VWD,
replacement of both plasma and platelet VWF by transfusion
is required to normalize the bleeding time, whereas plasma
VWF alone is insuﬃcient [9, 27, 88–90]. Dogs that have
no platelet VWF but normal plasma and endothelial VWF
have normal bleeding times [8]. In contrast to humans
and pigs with VWD, infusion of canine VWF into VWD
dogs nearly normalizes bleeding time [8]. Thus, bleeding
time, as a measure of hemostasis, appears to have species-
speciﬁcity related to VWF distribution in plasma, platelets,
and endothelium.
Organ transplantation can transfer the entire VWF gene
in situ and provides a model to study VWF function6 Thrombosis
in various compartments (Table 1). For example, bone
marrow transplantation in porcine VWD allows for separate
expressionofVWFintheplateletorplasma,endothelial, and
subendothelial compartments [9, 27, 28]. In these studies,
plasma VWF alone was suﬃcient to support bleeding time
and the development of occlusive arterial thrombosis in
the Folts arterial stenosis and injury model [9]. Likewise,
transplantation of normal liver and lungs into VWD pigs
hasprovidedcirculatingVWFwithoutplateletVWF[29,91].
The transplanted normal liver provides suﬃcient amounts of
plasma VWF to correct the bleeding time from >15 minutes
to ≤5m i n u t e s[ 26]. The transplanted normal lung, however,
provides ∼5% of normal VWF but is insuﬃcient to correct
the prolonged bleeding time. Thrombosis studies have not
been performed in the liver and lung transplantation exper-
iments. Thus, bleeding time prolongation in pigs appears to
occur when VWF is markedly decreased or absent from the
plasma and/or subendothelial compartments. The precise
role of platelet VWF in this scenario is unknown.
4.6. Gene Transfer. An inherited bleeding disorder such as
VWD is an attractive target for gene transfer using viral
vectors for several reasons. First, there is a single gene
defect. Second, the protein can be expressed from many
target organs that will secrete the transgene product into
plasma. Third, successful gene transfer would reduce the
requirement for blood products and the associated invasive
procedures required for administration which could very
realistically be expected to improve patient comfort and
well-being. Fourth, expression of VWF at relatively low
levels may provide some degree of phenotypic correction
from bleeding; overexpression, however, potentially could be
associated with thrombotic side eﬀects [1]. Contemporary
challenges for gene therapy are well recognized and VWF is
no exception [92–94]. Nonetheless, human VWF has been
expressed in blood outgrowth endothelial cells isolated from
VWD dogs [95], and progress has been made with murine
models [96, 97]. The availability of porcine and canine
VWF cDNA and newer gene transfer vectors provides an
opportunity to transferthis worktolarge animal models that
have a recognized strong preclinical predictive value [98].
4.7. Lung Xenotransplantation and VWD. Separate from
the role of VWF in hemostasis and thrombosis, lung
transplantation studies have focused on the binding of
porcine VWF and primate xenoreactive antibodies. Swine
pulmonary xenografts, as opposed to cardiac and renal
xenografts, release large amounts of porcine VWF when
transplanted into nonhuman primates. Human and non-
human primates have xenoreactive antibodies that bind
to carbohydrate side chains on porcine VWF [99]. Also,
porcine VWF spontaneously agglutinates human platelets
[2]. The absence of porcine VWF in VWD donor lungs
results in longer survival of the transplant in nonhuman
primates possibly due to mechanisms mediated by reduced
or absent VWF-mediated xenoantibody binding and platelet
agglutination [100]. These ﬁndings strongly support the
hypothesis that porcine VWF is a mediator of pulmonary
xenograft dysfunction and is a potential drug target for
improving xenograft survival.
4.8. Thrombotic Thrombocytopenia Purpura (TTP). Dis-
covery of the roles of VWF and its cleavage enzyme
ADAMTS13 in TTP has revolutionized the understanding
of the underlying mechanisms that mediate this previously
poorly understood disorder [101]. In studies performed
prior to this discovery, normal pigs and dogs injected with
botrocetin developed thrombocytopenia, microthrombi in
lungs and spleen but not kidney or brain, and initial
depletion of VWF multimers followed by the appearance
of ultra large VWF multimers during recovery. VWD pigs
and dogs were not aﬀected by botrocetin infusion suggesting
that plasma VWF mediates this botrocetin-induced throm-
botic thrombocytopenia in the absence of platelet VWF
[102]. Since ADAMTS13 had not been discovered when
these studies were performed, it was not assayed in these
animals. Recently, infusion of shiga toxin has been shown to
support the development of a thrombotic microangiopathy
in ADAMTS13-deﬁcient mice, but the eﬀect of the infusing
botrocetin on ADAMTS13 or in the absence of ADAMTS13,
if any, is unknown [103–106]. The ADAMTS13 cleavage site
is preserved in both porcine and canine VWF (Figure 2). It
is possible, then, that expression of porcine or canine VWF
in VWD pigs or dogs with mutations in the ADAMTS13
cleavage site, respectively, could result in a TTP syndrome.
Application of such information to the human condition
would need to consider the possibility that characterization
of ADAMTS13 is incomplete in many species and that
important functional diﬀerences may exist between them
[107].
Importantly, a novel approach to the treatment of
TTP in humans has been to neutralize VWF activity with
the aptamer ARC1779 [108, 109]. Administration of this
aptamer was well tolerated and appeared to be associated
with a signiﬁcant increase in platelet counts in a case of
refractory TTP. Currently, ARC1779 is being tested as an
“add-on” therapy to plasma exchange in patients with TTP.
4.9. Endocarditis Susceptibility. VWD swine appear to be
resistant to experimentally induced group C streptococ-
cal endocarditis, whereas normal pigs readily develop the
infection [110]. These data suggest that normal VWF-
mediated platelet function is necessary for establishing this
particular infection. Understanding of platelet function in
inﬂammation and infection is evolving rapidly, and pigs and
dogs with VWD likely will have a role in these studies [111–
113].
5. Summary and Conclusions
Pigs and dogs with VWD have provided faithful phenotypic
models for the study of basic aspects of human type
3VWD, as well as powerful tools for revealing pathogenesis,
developing new therapies, and testing their safety and
eﬃcacy. This conclusion is remarkable, considering the
important diﬀerences in porcine and canine VWF aminoThrombosis 7
acid sequence and reactivity to agonists such as ristocetin
and botrocetin. Both pigs and dogs, however, have proven
to be attractive species for studying VWF structure-function
relationships and VWF interactions with F.VIII, platelet
GP1b and αIIbβ3, collagen, and shear stress. In addition,
these animals have provided key insights into the roles of
platelet and plasma VWF in hemostasis and thrombosis. The
availability of full-length porcine and canine VWF cDNAs
opensthepossibilityofexpressingVWFwithdisease-causing
mutations that recapitulate other types of VWD, as recently
initiated in mice [114, 115]. Likewise, the recent cloning
of murine VWF cDNA and correction of bleeding time
prolongationinVWDmicebymurineVWFwillalsoprovide
importantmechanisticinsightsintotheprimaryroleofVWF
in hemostasis [116, 117]. The extensive characterization
of VWF and VWD in pigs, dogs, and mice will allow
investigatorstochoosethemostappropriatemodeltoanswer
the question at hand. Improved understanding of VWF-
mediated hemostasis and thrombosis in all such animals will
continuetocontributetobettermodelingandunderstanding
of human bleeding, thrombotic, and cardiovascular diseases.
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